1/30
12:53 am
mlys
Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones [Yahoo! Finance]
Medium
Report
Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones [Yahoo! Finance]
1/6
08:00 am
mlys
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
Low
Report
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
12/25
07:00 pm
mlys
Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge [Yahoo! Finance]
Low
Report
Is It Too Late To Consider Mineralys Therapeutics After Its Huge 2025 Share Price Surge [Yahoo! Finance]
12/24
07:01 pm
mlys
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow [Yahoo! Finance]
Low
Report
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow [Yahoo! Finance]
12/23
12:39 pm
mlys
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears [Yahoo! Finance]
Low
Report
Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears [Yahoo! Finance]
12/19
10:04 am
mlys
Mineralys Therapeutics (NASDAQ:MLYS) was given a new $52.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.
Medium
Report
Mineralys Therapeutics (NASDAQ:MLYS) was given a new $52.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.
12/12
11:00 am
mlys
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
Low
Report
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
11/29
08:50 am
mlys
A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital's Major New Investment [Yahoo! Finance]
Medium
Report
A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital's Major New Investment [Yahoo! Finance]
11/26
05:38 pm
mlys
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/26
04:05 pm
mlys
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
11/12
08:07 am
mlys
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at HC Wainwright from $52.00 to $56.00. They now have a "buy" rating on the stock.
Low
Report
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at HC Wainwright from $52.00 to $56.00. They now have a "buy" rating on the stock.
11/11
09:44 am
mlys
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at Wells Fargo & Company from $50.00 to $55.00. They now have an "overweight" rating on the stock.
Medium
Report
Mineralys Therapeutics (NASDAQ:MLYS) had its price target raised by analysts at Wells Fargo & Company from $50.00 to $55.00. They now have an "overweight" rating on the stock.
11/11
12:30 am
mlys
Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]
Medium
Report
Mineralys Therapeutics Inc (MLYS) Q3 2025 Earnings Call Highlights: Strong Financial Position ... [Yahoo! Finance]
11/10
04:19 pm
mlys
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/10
04:05 pm
mlys
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Medium
Report
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update